Background {#Sec1}
==========

*Streptococcus pneumoniae* is a major cause of morbidity and mortality in infants, children, and older adults (≥ 65 years), causing pneumonia and invasive pneumococcal diseases (IPDs) worldwide \[[@CR1]--[@CR3]\]. The disease burden is rapidly worsening in many countries due to the increasing number of people affected by chronic diseases and the increasing disease risks in older age groups \[[@CR4], [@CR5]\]. Although IPD is the most severe form with the highest case fatality rate, non-bacteremic pneumonia is the most common manifestation of pneumococcal disease in adults \[[@CR5]\]. The population of China is the largest in the world and, given its economic development and improved medical conditions in recent decades, the aging Chinese population is growing; therefore the prevention and control of pneumococcal infections has become an important public health challenge.

Antibiotics are the primary choice for treatment of pneumococcal infections. However, increasing resistance of pneumococci to conventional antibiotics has made the role of antibiotics in the treatment of infection more and more limited \[[@CR6]\]. Vaccination has proven to be an effective means of preventing pneumococcal infection worldwide. Immunization with 7-valent pneumococcal conjunctive vaccine (PCV7) and 23-valent pneumococcal polysaccharide vaccine (PPV23) has been recommended for children younger than 24 months of age, high-risk groups, and older adults. For children, PCV7 became commercially available in China in 2008 and was replaced by the 13-valent pneumococcal conjugate vaccine (PCV13) in 2017. Currently, PCV7 is not included in the national immunization program and PCV7 immunization is given only on an individual basis.

A previous study showed that serotype distribution varies with geographical location and age \[[@CR7]\]. To effectively control pneumococcal disease in China, the serotype combinations included in vaccines must closely match the distribution of pneumococcal serotypes. Therefore, it is necessary to determine the epidemiology of *S. pneumoniae* after vaccination with the PCV7 available in China. This study analyzed the antimicrobial resistance, serotype distribution, and molecular epidemiology characteristics of 881 pneumococcal isolates from multiple hospitals in China from 2011 to 2016.

Methods {#Sec2}
=======

Bacterial isolates {#Sec3}
------------------

This study was conducted at the Peking University People's Hospital, a teaching hospital located in Beijing, China. A total of 881 *S. pneumoniae* isolates were collected from pediatric and adult patients with pneumococcal infections in 17 cities across China during the years 2011, 2012, 2013, and 2016. The study protocols were approved by Ethics Committee of the Pecking University People's Hospital and all participants provided written informed consent prior to study commencement. For participants younger than 18 years of age, written informed consent was obtained from each participant's parents or legal guardian. One isolate was collected from each patient. Duplicate isolates and patients colonized by bacteria but without any clinical evidence of infection were excluded. Isolates were obtained from sputum, blood, broncho-alveolar lavage fluid (BALF), cerebrospinal fluid (CSF), pharyngeal swabs, nasal swabs, and middle ear fluid. Sputum samples from children \< 2 years old were collected by nasotracheal aspiration. *S. pneumoniae* isolates from sputums were included if they met the following criteria: less than 10 squamous epithelial cells and more than 25 leukocytes per low power field. Isolates were transported to Peking University People's Hospital for antibiotic susceptibility testing and serotyping annually. Isolates were identified based on typical colony morphology, Gram staining, optochin sensitivity tests (Oxoid, Hampshire, UK), and Omni serum assays (Statens Serum Institut, Copenhagen, Denmark).

In vitro antimicrobial susceptibility testing {#Sec4}
---------------------------------------------

The agar dilution method was used to determine the minimum inhibitory concentrations (MICs) of the 881 *S. pneumoniae* isolates against 15 antibiotics (penicillin, amoxicillin/clavulanic acid, ceftriaxone, cefuroxime, cefaclor, vancomycin, erythromycin, azithromycin, clarithromycin, tetracycline, levofloxacin, moxifloxacin, trimethoprim/sulfamethoxazole, chloramphenicol and clindamycin) in accordance with the guidelines established by the Clinical and Laboratory Standards Institute (CLSI) \[[@CR8]\]. The CLSI 2013 criteria for MICs were applied to classify isolates as susceptible, intermediate, or resistant. The oral penicillin breakpoint was used to classify isolates as penicillin-susceptible (MIC ≤ 0.06 μg/ml), penicillin-intermediate (MIC between 0.12 and 1 μg/ml), or penicillin-resistant (MIC ≥ 2 μg/ml). For ceftriaxone, the non-meningitis breakpoint was used to classify isolates as susceptible (MIC ≤ 1 μg/ml) or resistant (MIC ≥ 4 μg/ml) \[[@CR9]\]. *S. pneumoniae* ATCC 49619 was used as the quality control strain and was included in each set of tests to ensure accurate results. MICs were calculated as the MIC~50~ and MIC~90~ (MICs that inhibit 50% and 90% of the isolates, respectively).

Pneumococcal serotyping {#Sec5}
-----------------------

Pneumococcal serotypes/groups were determined for the 881 isolates with Pneumotest-Latex kit (Statens Serum Institut, Copenhagen, Denmark) and type-specific antisera (Statens Serum Institut, Copenhagen, Denmark). The Pneumotest-Latex kit consisted of the 14 latex reagents pools A-I and P-Q. By testing all 14 pools and using the chessboard identification system, it was possible to identify the 23 vaccine serotypes to type/group level. Traditional quellung reaction with type-specific antisera was used for full serotyping of serogroup 19, 6 and 23. Isolates that reacted with the Pneumotest-Latex kit but did not belonged to serotypes or groups included in the PPV23 were classified as Non-vaccine types (NVT). The potential PCV7 and PCV13 vaccine coverage was estimated by calculating the percentage of isolates that expressed the serotypes included in the vaccines and related serotypes (7 for 7F, 9 for 9 V, and 18 for 18C).

Multilocus sequence typing (MLST) procedure {#Sec6}
-------------------------------------------

Multilocus sequence typing (MLST) analysis was performed according to the *S. pneumoniae* MLST protocol \[[@CR10]\]. Internal fragments of approximately 550--600 bp from the *aroE*, *gdh*, *gki*, *recP*, *spi*, *xpt*, and *ddl* genes were amplified by polymerase chain reaction using primers described previously \[[@CR11]\]. Alleles and sequence types (STs) were assigned using software available at the *Streptococcus pneumoniae* MLST Database web page (<http://pubmlst.org/spneumoniae>). Analysis of STs and assignment to clonal complexes were performed using all STs found in the online database using the eBURST program. STs were grouped into clonal complexes by their similarity to a central allelic profile. Visualization of phylogenetic results was performed using the PHYLOViZ online tool (<http://www.phyloviz.net>/).

Statistical analysis {#Sec7}
--------------------

Data from the antibiotic susceptibility tests were analyzed using WHONET 5.6 software, Windows-based database software developed by the World Health Organization for the management and analysis of microbiological laboratory data with a special focus on the analysis of antimicrobial susceptibility test results. χ^2^ and Fisher's exact probability tests were performed using SPSS for Windows (version 18.0; SPSS, Chicago, IL, USA) to compare proportions. *P* values \< 0.05 were considered statistically significant.

Results {#Sec8}
=======

Profile of pneumococcal isolates {#Sec9}
--------------------------------

During the study period, a total of 881 non-duplicated isolates were collected from 23 teaching hospitals in 17 cities. The number of isolates varied with years and regions and it was detailed in the Additional file [1](#MOESM1){ref-type="media"}: Table S1. Of the 881 *S. pneumoniae* isolates, 131 were obtained from pediatric patients aged 0 to 2 years (≤ 2 years old), 45 were obtained from pediatric patients aged 2 to 5 years (\> 2 but ≤ 5 years old), 43 were obtained from patients aged 5 to 18 years (\> 5 but ≤ 18 years old), 408 were obtained from adults aged 18 to 65 years (\> 18 but ≤ 65 years old), and 254 were obtained from patients \> 65 years old. Sputum was the most common specimen source, accounting for 73.1% of samples (644 strains), followed by blood (56 strains), BALF (56 strains), pharyngeal swabs (22 strains) and CSF (13 strains) Table [1](#Tab1){ref-type="table"}. Strains isolated from sterile sites, such as blood, CSF, and pleural fluid, were classified as IPD strains. The 17 cities were divided into three groups based on the per capita gross domestic product (GDP) of the province in which the city is located (China Statistical Yearbook 2016, <http://www.stats.gov.cn/tjsj/ndsj/2016/indexeh.htm>). Cities in group 1 had a per capita GDP of more than 60,000 Chinese yuan (CNY) and included Tianjin, Beijing, Shanghai, Jiangsu, Zhejiang, Inner Mongolia, Guangdong, and Shandong. Cities in group 2 had a per capita GDP between 50,000 and 60,000 CNY and included Chongqing, Hubei, Jilin, Shaanxi, and Liaoning. Cities in group 3 had a per capita GDP of less than 50,000 CNY and included Ningxia, Hunan, Xinjiang, and Guangxi.Table 1Distribution of *Streptococcus pneumoniae* specimens by age group and year collectedSpecimen typeNumber%Age groupsYears≤ 2 years\> 2 and ≤ 5 years\> 5 and ≤ 18 years\> 18 and ≤ 65 years\> 65 years2011201220132016Sputum64473.1121332625920534210166234Blood566.433335123181718Broncho-alveolar lavage566.413718131726Pharyngeal swabs222.5364813847Cerebrospinal fluid131.5193247Eye secretion101.122511144Secretion91.0115254Pus80.916144Nasal swabs60.72433Wound swab60.751231Pleural fluid60.75124Tissue60.72451Sinus swab40.5224Tracheal40.5314Middle ear fluid30.311112Abdominal fluid30.3312Bile20.2211Urine20.2211Bone marrow10.111Vaginal swab10.111Not specified192.21215119

Antimicrobial susceptibility of *Streptococcus pneumoniae* {#Sec10}
----------------------------------------------------------

The in vitro activities of the tested antimicrobial agents against the 881 *S. pneumoniae* strains are shown in Table [2](#Tab2){ref-type="table"}. Based on the MIC breakpoints of oral penicillin, the percentages of penicillin-resistant *S. pneumoniae* (PRSP), penicillin-intermediate *S. pneumoniae* (PISP), and penicillin-susceptible *S. pneumoniae* (PSSP) isolates were 51.6% (455/881), 12.3% (108/881), and 36.1% (318/881), respectively. The rates of resistance of *S. pneumoniae* to erythromycin, azithromycin, and clarithromycin were 95.2%, 96.9%, and 92.5%, respectively. Macrolides exhibited weak activity against all of the isolates. Of the 839 strains (95.2%) that were resistant to erythromycin, 776 (92.5% of all strains) were also resistant to clindamycin. *S. pneumoniae* susceptibilities to amoxicillin/clavulanic acid and ceftriaxone were comparable (using non-meningitis breakpoints), but the rate of resistance to amoxicillin/clavulanic acid was higher than to ceftriaxone (using non-meningitis breakpoints). Overall, the resistance of *S. pneumoniae* to penicillin (based on breakpoints of oral penicillin) increased from 48.8% in 2011 to 55.9% in 2016 (*P* = 0.390, Fig. [1](#Fig1){ref-type="fig"}). The proportion of PRSP isolates remained stable and there were no statistical differences in rates of PRSP from 2011 to 2016 (Table [3](#Tab3){ref-type="table"}). During the same time period, the proportion of PSSP isolates fell from 39% in 2011 to 33.6% in 2016. The MIC~50~ of penicillin was 1 μg/ml in 2011 and increased to 2 μg/ml in 2016, indicating a trend towards an increase in resistance to penicillin. Trends towards increases in resistance were also observed for other β-lactams and cephalosporins. However, fluoroquinolones maintained excellent activity against *S. pneumoniae*; the MIC~90~ values for levofloxacin and moxifloxacin were 1 μg/ml and 0.25 μg/ml, respectively. There were 19 *S. pneumoniae* strains resistant to levofloxacin and the MIC values were between 8 and 32 μg/ml. All of the strains were susceptible to vancomycin and no vancomycin-resistant strains were found during the study period. The rates of resistance of penicillin non-susceptible *S. pneumoniae* (PNSP) to other antimicrobial agents were also significantly higher than those of PSSP. However, no statistical differences in resistance to azithromycin, clarithromycin, levofloxacin, or moxifloxacin were found between PSSP and PNSP strains. The proportion of PSSP isolates varied with patient age; PSSP was more common among older adults compared with children (42.0% vs 18.7%, *P* \< 0.001). There were no significant differences in the proportion of PNSP isolates between IPD and non-IPD strains. The rate of PSSP isolated from patients in emergency units was higher than in other hospital wards (*P* = 0.041). Similarly, the rate of PNSP isolated from patients in intensive care units (ICUs) was higher than in other wards (*P* = 0.017, Table [3](#Tab3){ref-type="table"}).Table 2In vitro activity of 14 antimicrobial agents against 881 isolates of *Streptococcus pneumoniae*Antimicrobial agentPSSP (*n* = 318)PISP (*n* = 108)PRSP (*n* = 455)PR%MIC~50~MIC~90~MIC rangeR%MIC~50~MIC~90~MIC rangeR%MIC~50~MIC~90~MIC rangePenicillin (oral)00.0160.032.004--.064011.125--1100442--64---Amoxicillin/clavulanic acid0.30.0160.032.008--32012.008--260.7816.016--128\<  0.00001Ceftriaxone (non meningitis)00.0160.064.016--10.90.51.016--440.728.25--512--Cefuroxime oral0.60.0320.125.016--845.424.016--3297.81632.008--512\< 0.00001Cefaclor2.212.016--3288.91282561--512-99.8\>256\>2562--512-\< 0.00001Vancomycin00.250.25.008--.500.250.5.064--.500.250.25.064--1--Erythromycin8916\>256.016--51296.332\>256.032--51299.3\>256\>256.032--512\< 0.00001Azithromycin94.632\>256.016--51294.432\>256.032--51299.3\>256\>256.032--5120.135Clarithromycin88.332\>256.016--51280.632\>256.016--51298.6\>256\>256.032--5120.063Tetracycline84.63264.064--12892.61664.25--6497.13264.25--128\< 0.00001Levofloxacin1.311.025--325.611.25--32211.5--640.163Moxifloxacin0.60.1250.25.016--161.90.1250.25.016--80.70.1250.25.016--160.666Trimethoprim/sulfamethoxazole34.90.58.032--6460.248.064--3289.5816.125--128\< 0.00001Clindamycin74.2128256.016--51288128256.016--25697.8256256.016--512\< 0.00001 Fig. 1Changes in resistance of *S. pneumoniae* to different antimicrobial agents from 2011 to 2016 Table 3Proportion of PSSP and PNSP isolates by age, year, and vaccination statusGroupsNumber of isolatesPSSP %PNSP %*P* valueAge≤ 2 years13119.180.9\< 0.00001\>  2 and ≤ 5 years4515.684.40.003083\> 5 and ≤ 18 years4320.979.10.032561\> 18 and ≤ 65 years40842.257.80.000646\> 6525441.758.30.029919Years20114139610.700859201227039.360.70.210449201323735.964.10.897489201633333.666.40.215055PCV7\< 0.00001PCV7 covered33012.187.9PCV13\< 0.00001PCV13 covered51414.885.2IPD0.223755IPD7542.757.3Ward typesunknown2536640.982413emergency5549.150.90.040078out patient10334660.616566in patient63536.963.10.524408ICU6322.277.80.016520Major serotypes19F2263.596.5\< 0.0000119A1235.794.3\< 0.00001155846.653.40.0899386B3119.480.60.0468336A263.896.20.00049117258416\< 0.0000114210100--23F1910.589.50.018531NVT23469.230.8\< 0.00001

### Serotyping and vaccine coverage {#Sec11}

Of the 881 isolates, 234 isolates were non-typable and 22 different kinds of serotypes were identified. The serotype distribution of these *S. pneumoniae* isolates is shown in Fig. [2](#Fig2){ref-type="fig"}. Among the typable isolates, 19F (25.7%), 19A (14.0%), 15 (6.8%), 6B (3.6%), 6A (3.0%), and 17 (2.8%) were the most common serotypes. The most common serotypes in all age groups were 19F and 19A.Fig. 2Distribution and proportion of 881 *S. pneumoniae* strains collected between 2011 and 2016. N23F strains belong to serogroup 23 but not serotype 23F. NVT: serotypes not included in the PPV23. Serotypes 4, 6B, 9, 14, 18, 19F, and 23F are included in PCV7. Serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9, 14, 18C, 19A, 19F, and 23F are included in PCV13

The overall vaccine coverage rates for PCV7 and PCV13, which include isolates 1, 3, 5, 6A, 7, and 19A, were 37.5% and 58.3%, respectively. Importantly, vaccine coverage rates varied by patient age; vaccine coverage rates in young children were significantly higher than in older adults (Table [4](#Tab4){ref-type="table"}).Table 4Coverage (%) of PCV7 and PCV13 in different age groups from 2011 to 2016Age groupsPCV7 coveredPCV13 covered20112012201320162011201220132016≤ 2 years42.948.137.255.671.474.162.859.3\> 2 and ≤ 18 years5052.641.737.862.584.270.864.9\> 18 and ≤ 65 years43.831.536.731.862.556.55251.2\> 65 years3041.138.935.44058.963.953.5

Immunization coverage in this study varied considerably by geographic area. The highest coverage of PCV7 and PCV13 was in Jiangsu with rates of 63.2% and 78.9%, respectively. In contrast, the lowest coverage was in Jilin with rates of 12.9% and 32.3%, respectively. We also found that vaccine coverage was associated with economic development. There was no difference in PCV7 or PCV13 coverage between groups 1 and 2, whereas PCV7 and PCV13 coverage was significantly higher in group 3 compared with groups 1 and 2 (Table [5](#Tab5){ref-type="table"}).Table 5Coverage (%) of PCV7 and PCV13 in different regions in ChinaGroup by GDPProvinceNumbernon-PCV7 covered (%)PCV7 covered (%)*P* valuenon-PCV13 covered (%)PCV13 covered (%)*P* valueGroup 1Beijing175120 (68.6)55 (31.4)84 (48.0)91 (52.0)Group 1Guangzhou9150 (54.9)41 (45.1)25 (27.5)66 (72.5)Group 1Zhejiang8261 (74.4)21 (25.6)44 (53.7)38 (46.3)Group 1Jiangsu3814 (36.8)24 (63.2)8 (21.1)30 (78.9)Group 1Inner Mongolia1911 (57.9)8 (42.1)11 (57.9)8 (42.1)Group 1Shandong2920 (69.0)9 (31.0)13 (44.8)16 (55.2)Group 1Shanghai5934 (57.6)25 (42.4)24 (40.7)35 (59.3)Group 1Tianjin5033 (66.0)17 (34.0)29 (58.0)21 (42.0)Group 1543343 (63.2)200 (36.8)0.627101238 (43.8)305 (56.2)0.097211Group 2Chongqing7944 (55.7)35 (44.3)30 (38.0)49 (62.0)Group 2Jilin3127 (87.1)4 (12.9)21 (67.7)10 (32.3)Group 2Liaoning4437 (84.1)7 (15.9)20 (45.5)24 (54.5)Group 2Hubei5231 (59.6)21 (40.4)22 (42.3)30 (57.7)Group 2Shaanxi3115 (48.4)16 (51.6)7 (22.6)24 (77.4)Group 2237154 (65.0)83 (35.0)0.364746100 (42.2)137 (57.8)0.844537Group 3Hunan115 (45.5)6 (54.5)3 (27.3)8 (72.7)Group 3Guangxi75 (71.4)2 (28.6)3 (42.9)4 (57.1)Group 3Ningxia3919 (48.7)20 (51.3)10 (25.6)29 (74.4)Group 3Xinjiang4425 (56.8)19 (43.2)13 (29.5)31 (70.5)Group 310154 (53.5)47 (46.5)0.04516929 (28.7)72 (71.3)0.005041

The sensitivities of the *S. pneumoniae* serotypes to antimicrobial agents varied significantly. In serogroups 19 (including 19F and 19A), 6 (including 6A and 6B), 14, and 23F, the proportion of PNSP isolates was significantly higher compared with the other common serotypes (Table [3](#Tab3){ref-type="table"}), whereas the proportion of PSSP isolates was higher in serotypes 15 and 17 and in the non-typable strains. The proportion of PNSP isolates was higher among vaccine-covered strains (87.9% for PCV7 and 85.2% for PCV13) than non-covered strains (49.4% for PCV7 and 33.8% for PCV13).

### Multilocus sequence typing {#Sec12}

Of the 881 strains, 424 (strains isolated in 2016 were not tested by MLST) were identified as 82 STs. Among the tested strains, ST271 (120, 28.3%), ST320 (73, 17.2%), and ST81 (27, 6.6%) were the most common STs. Of the 19F isolates that were identified with specific STs, 98 (77.8%) were ST271 and 15 (11.9%) were ST320. Of the 19A isolates, 55 (75.3%) were ST320 and 15 (20.6%) were ST271. We found that 19F--ST271 and 19A--ST320 isolates were more resistant to several of the tested antibiotics, especially β-lactams (Table [6](#Tab6){ref-type="table"}). The phylogenetic tree generated using the PHYLOViZ online tool showed that all of the tested strains exhibited obvious clonal aggregation, with the vast majority of the population made up of resistant clones and serotypes, whereas susceptible clones and serotypes showed a decentralized pattern (Fig. [3](#Fig3){ref-type="fig"}).Table 6Sequence types, serotypes, antibiotic resistance rates (%), and age distributions for 424 *Streptococcus pneumoniae* isolates analyzed by MLSTClonal ComplexSTNumberSerotypes (Number)Resistance rates of different antibioticsNumber of strains in different agesPenicillinLevofloxacinErythromycin\<= 2(2,5\](5,18\](18,65\]\> 65CC27127112019F(98), 19A(15), NVT(5), 15(1), 1(1)97.50100357941283207319A(55), 19F(15), 18(1), 15(1), NVT(1)98.62.7100121002922236619F(5), NVT(1)83.316.7100100321937219F(2)100010000011CC81812823F(8), 15(6), NVT(6), N23F(3), 6B(2), 3(1), 17(1), 18(1)92.93.610053015583119F(1)100010010000CC8768761714(11), NVT(3), 18(2), 4(1)47.15.91002301025749114(1)0010000001CC50550514NVT(9), 3(3), 17(1), 19F(1)0092.90026612,4492NVT(2)0010000020CC18018013NVT(12), 8(1)7.7092.3100842971NVT(1)0010000001CC33973397915(7), 8(2)0088.9310327768315(3)33.301002100010,098115(1)0010010000CC12636011415(2), 4(1), NVT(1)0010000022466029(1), NVT(1)0010000020126329(1), NVT(1)001000001128011(1)00010CC59726946417(3), 8(1)0251000002259723NVT(2), 5(1)0010000021775923(1), NVT(1)50010000020CC275427546NVT(3), 15(2), 8(1)001000005177521NVT(1)0010000001CC3173317356A(4), 6B(1)800100400106340119F(1)100010000001CC2758275817(1)00100100007402111(1)001000000111,9671NVT(1)0010000001CC338733872NVT(2)00100200009016B(1)0010010000CC2912291216B(1)0000000187381NVT(1)100010010000CC342342117(1)0010000001632511(1)0010000010Singletons978976B(3), 6A(2), NVT(2)1000100200416202715(6), 10(1)00100000709951(1),3(1),4(1),5(1),19F(1)001000002343894NVT(4)005000013OTHER69NVT(22), 17(7), 18(6), 15(4), 19A(3), 1(2), 14(2), 19F(2), 2(2), 20(2), 22(2), 23F(2), 3(2), 7(2), 8(2), 9(2), N23F(2), 4(1), 6A(1), 6B(1)14.5089.916333017 Fig. 3Phylogenetic tree of 424 S. pneumoniae strains generated by the PHYLOViZ online tool

Discussion {#Sec13}
==========

Infections caused by *S. pneumoniae* have traditionally been treated with β-lactams, to which this species was extremely sensitive when penicillin was first introduced in the 1940s \[[@CR12]\]. However, resistance was first observed in the 1960s and has continued to increase throughout the world in recent decades \[[@CR12], [@CR13]\]. The emergence of resistance to penicillin and other β-lactam antibiotics in pneumococci has led to the increased adoption of macrolides, fluoroquinolones, and other non-β-lactam antibiotics to treat pneumococcal infections \[[@CR14]\]. However, resistance to antimicrobials continues to increase, complicating efforts to treat pneumococcal disease in both adults and children.

The data from this study showed that *S. pneumoniae* isolated from adults and children during the investigation period were highly resistant to β-lactams, macrolides, and trimethoprim/sulfamethoxazole, which is consistent with a previous study \[[@CR15]\]. Based on the MIC breakpoints of oral penicillin, the proportion of PRSP increased from 48.8% in 2011 to 55.9% in 2016. MICs of most of the antimicrobial agents tested against PRSP were higher than against PSSP, indicating co-resistance between these antimicrobials. Consequently, the increasing prevalence of multidrug resistant (MDR) in *S. pneumoniae* in China is becoming a serious health threat.

Macrolides, including erythromycin, azithromycin, and clarithromycin, had the lowest antibacterial activity against both PNSP and PSSP strains, with MIC~90~ values greater than 256 μg/ml. Since the early 1990s, the American Thoracic Society treatment guidelines have listed macrolide antibiotics as the first-line empiric therapy for outpatients with community-acquired pneumonia \[[@CR16]\], resulting in the widespread use of these agents. In Europe, resistance of *S. pneumoniae* to erythromycin has been reported to be between 14.7 and 17.1% \[[@CR17]\]. However, more than 90% of clinical *S. pneumoniae* strains in this study were found to be resistant to macrolides; therefore macrolides should be used cautiously as empiric therapy against pneumococcal infection in China. Abuse of macrolides in outpatient practices and the clonal spread of MDR strains is likely responsible for the high prevalence of macrolide resistance in China \[[@CR18]\]. Additionally, macrolide-resistant *S. pneumoniae* strains identified in this study were found to be co-resistant to other antibacterials, such as tetracycline (94.2%), clindamycin (92.5%), and penicillin (53.9%; oral penicillin V). Other researchers have shown that the majority of MDR *S. pneumoniae* in China are macrolide-lincosamide-streptogramin B resistant and that they carry the *erm(B)* gene \[[@CR19]\]. Multiple antibiotic resistance is widespread in China and an increase in MDR *S. pneumoniae* strains has also been observed in other parts of Asia such as Japan, Korea, and Taiwan \[[@CR20]\]. In contrast, fluoroquinolones showed exceptional activity against *S. pneumoniae* in this study, which is in accordance with other reports \[[@CR18], [@CR21], [@CR22]\], indicating that fluoroquinolones could be a better option for the treatment of pneumococcal infections in adult patients.

Interestingly, in this study, strains isolated from patients in emergency units were more susceptible to penicillin, whereas strains isolated from patients in ICUs were more resistant to penicillin. This could indicate that *S. pneumoniae* strains within the community were more susceptible to penicillin, whereas more resistant strains, for which treatments were more likely to fail, developed within medical institutions.

In this study, the proportion of PNSP isolates in serotypes 19F, 19A, and 6B was higher than in other serotypes. Previous studies have indicated that recombination efficiency varies with *S. pneumoniae* serotype, with certain strains having been identified as particularly efficient at recombination. For example, serotypes 3 and 18C were found to be much less transformable with a selective marker compared with 19F, 19A, 23F, 6B, and 14 \[[@CR23]\]. Interspecies and intraspecies genetic transformations likely play an important role in most multi-antimicrobial resistance mechanisms in pneumococci \[[@CR24]\].

Vaccination is an alternative method of preventing pneumococcal infection. It has been reported that the prevalence of vaccine-covered serotypes decreased significantly after large-scale application of PCV7. Studies have shown that the introduction of pneumococcal conjugate vaccines has not only reduced the burden of pneumococcal disease in children \[[@CR25]\], but has also greatly impacted the burden of disease in adults by preventing the spread of vaccine-related resistant strains to adults \[[@CR26], [@CR27]\]. PCV7, which was replaced by PCV13 in 2016, has been used in China since 2008 on an individual basis. In this study, the average vaccine coverage of PCV7 (37.5%) and PCV13 (58.3%) in the population was similar to the vaccine coverage before they were introduced into China \[[@CR28]\], suggesting that the effects of PCV7 and PCV13 in China were limited. Exclusion from the national immunization program and high prices could be responsible for low vaccination rates and poor herd immunity in the target population \[[@CR29]\]. We also found that in areas with better economic development, vaccine coverage was lower than in less economically developed regions. This is likely due to historically higher rates of vaccine use in economically developed regions, resulting in greater herd protection and a subsequent decline in the rate of vaccine coverage. Considering the protective effect of vaccines reported in other countries and the high coverage of PCV13 in both children and adults in China, inclusion of PCV13 in the national immunization program could result in significant changes in the serotype distribution of *S. pneumoniae* in both children and adults.

There were some limitations to this study. Most importantly, all strains were obtained from sophisticated medical institutions, whereas no strains were obtained from community-based clinics. Patients are typically admitted to large medical institutions when empirical treatment has failed or when existing diseases worsen. Patients infected with strains that have lower levels of resistance and virulence are more likely to be cured by the empirical treatment regimen and would not need to go to a large hospital for further medication. Because of this screening mechanism, the data from this study only explain resistance and serotype distribution status of *S. pneumoniae* isolated from hospitals. Additionally, while the effect of PCV13 has been evaluated mainly in IPD strains \[[@CR30]\], the number of IPD strains in this study was very limited. This may be due to less blood cultures were prescribed in China. The proportion of blood cultures in all microbiology specimens varied with hospitals in this study, ranging from 20% to 50%. The percentages of blood-cultures were higher in large cities and teaching hospitals and were lower in small cities and primary hospitals. In China, doctors diagnose respiratory infections relied a lot on X-ray imaging findings and white blood cell count, both of them returned results on the same day. Although doctors also prescribed microbiology cultures (usually sputum culture) pathogen detection, doctors may empirically use antibiotics if X-ray imaging and white blood cell count indicating a bacterial infection. Further study on IPD strains is required to assess the effectiveness of the PCV13 vaccine in China. The number of strains varied with years and regions, and the number of strains in some years and regions was relatively small. A very small sample size would inevitably introduce random errors, especially in the comparison of vaccine coverage rates between different age groups and regions. Therefore, in order to clarify the resistance and serotype distribution of *S. pneumoniae* in the population, our future studies will assess strains from primary health care institutions in the community.

Conclusions {#Sec14}
===========

High resistance to β-lactams and macrolides was observed of all 881 *S. pneumoniae* strains. However, fluoroquinolones maintained excellent activity against *S. pneumoniae*. Drug resistance varied among different serotypes and age groups. Serotypes 19F, 19A, 15, 6B, 6A and 17 were the most common serotypes. The serotype 19F, 19A, 6A, 6B, 14 and 23F demonstrated higher resistance compared with other serotypes. Vaccine coverage in this study varied considerably associated geographic area and economic development. Through molecular biology analysis, obvious clonal aggregation was observed. Community-acquired and more invasive strains should also be included in future studies to gain a better understanding of the prevalence and resistance of *S. pneumoniae* in China.

Additional file {#Sec15}
===============

Additional file 1: Table S1.Number of *Streptococcus pneumoniae* strains in different cities and years. This table describes the numbers of strains in different cities and years. The cities in this table were divided into 3 group based on the annual per capita GDP. (DOCX 16 kb)

ATCC

:   American Type Culture Collection

BALF

:   Broncho-alveolar lavage fluid

CLSI

:   Clinical and Laboratory Standards Institute

CNY

:   Chinese yuan

CSF

:   Cerebrospinal fluid

GDP

:   Gross domestic product

ICU

:   Intensive care unit

IPD

:   Invasive pneumococcal disease

MDR

:   Multidrug resistant

MIC

:   Minimum inhibitory concentration

MLST

:   Multilocus sequence typing

PCV13

:   13-valent pneumococcal conjugate vaccine

PCV7

:   7-valent pneumococcal conjunctive vaccine

PISP

:   Penicillin-intermediate *S. pneumoniae*

PNSP

:   Penicillin non-susceptible *S. pneumoniae*

PPV23

:   23-valent pneumococcal polysaccharide vaccine

PRSP

:   Penicillin-resistant *S. pneumoniae*

PSSP

:   Penicillin-susceptible *S. pneumoniae*

ST

:   Sequence type

SXT

:   Trimethoprim/sulfamethoxazole
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